Literature DB >> 32801297

Targeting subclinical organ damage in obstructive sleep apnea: a narrative review.

Cesare Cuspidi1,2, Marijana Tadic3, Elisa Gherbesi4, Carla Sala4, Guido Grassi5.   

Abstract

Subclinical abnormalities in cardiac and vascular structure reflect the adverse effects triggered by a variety of risk factors on the cardiovascular (CV) system thereby representing an intermediate step in the cardiovascular continuum; such alterations are recognized as reliable markers of increased cardiovascular risk in different clinical settings including obstructive sleep apnea (OSA). The mechanisms underlying subclinical organ damage (OD) in the OSA setting are multifactorial. Hypoxemia and hypercapnia, induced by repeated collapses of upper airways, have been suggested to trigger a cascade of events such as activation of the sympathetic tone, renin-angiotensin-aldosterone system leading to endothelial dysfunction, vasoconstriction, myocardial and vascular remodeling, and hypertension. Furthermore, coexisting non-haemodynamic alterations such as increased oxidative stress, release of inflammatory substances, enhanced lipolysis and insulin resistance have been reported to play a role in the pathogenesis of both cardiac and extra-cardiac OD. In this article we reviewed available evidence on the association between OSA and subclinical cardiac (i.e., left and right ventricular hypertrophy, left atrial dilatation) and extra-cardiac organ damage (i.e., carotid atherosclerosis, arterial stiffness, microvascular retinal changes, and microalbuminuria). This association is apparently stronger for cardiac and carotid subclinical damage than for other markers (i.e., arterial stiffness and retinal changes) and mostly evident in the setting of severe OSA.

Entities:  

Year:  2020        PMID: 32801297     DOI: 10.1038/s41371-020-00397-0

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  74 in total

Review 1.  Cardiovascular Consequences of Obstructive Sleep Apnea.

Authors:  Brynn K Dredla; Pablo R Castillo
Journal:  Curr Cardiol Rep       Date:  2019-11-09       Impact factor: 2.931

2.  Intrathoracic pressure swings induced by simulated obstructive sleep apnoea promote arrhythmias in paroxysmal atrial fibrillation.

Authors:  Christian Schlatzer; Esther I Schwarz; Noriane A Sievi; Christian F Clarenbach; Thomas Gaisl; Laurent M Haegeli; Firat Duru; John R Stradling; Malcolm Kohler
Journal:  Europace       Date:  2015-05-19       Impact factor: 5.214

3.  Prevalence of comorbidities in patients with obstructive sleep apnea syndrome, overlap syndrome and obesity hypoventilation syndrome.

Authors:  Donato Lacedonia; Giovanna Elisiana Carpagnano; Giulia Patricelli; Mauro Carone; Crescenzio Gallo; Incoronata Caccavo; Roberto Sabato; Annarita Depalo; Maria Aliani; Alberto Capozzolo; Maria Pia Foschino Barbaro
Journal:  Clin Respir J       Date:  2018-01-16       Impact factor: 2.570

4.  Angiotensin Receptor Expression and Vascular Endothelial Dysfunction in Obstructive Sleep Apnea.

Authors:  Rami N Khayat; Saradhadevi Varadharaj; Kyle Porter; Angela Sow; David Jarjoura; Mikhail A Gavrilin; Jay L Zweier
Journal:  Am J Hypertens       Date:  2018-02-09       Impact factor: 2.689

Review 5.  Sympathetic Nervous System, Sleep, and Hypertension.

Authors:  Gino Seravalle; Giuseppe Mancia; Guido Grassi
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

6.  Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity.

Authors:  Guido Grassi; Anna Facchini; Fosca Quarti Trevano; Raffaella Dell'Oro; Francesca Arenare; Francesco Tana; GianBattista Bolla; Anna Monzani; Maria Robuschi; Giuseppe Mancia
Journal:  Hypertension       Date:  2005-06-27       Impact factor: 10.190

7.  Left ventricular hypertrophy and renal dysfunction during antihypertensive treatment adversely affect cardiovascular prognosis in hypertensive patients.

Authors:  Massimo Salvetti; Maria L Muiesan; Anna Paini; Cristina Monteduro; Claudia Agabiti-Rosei; Carlo Aggiusti; Fabio Bertacchini; Deborah Stassaldi; Maurizio Castellano; Enrico Agabiti-Rosei
Journal:  J Hypertens       Date:  2012-02       Impact factor: 4.844

8.  Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels.

Authors:  Cristiana Catena; GianLuca Colussi; Marica Valeri; Leonardo A Sechi
Journal:  Am J Hypertens       Date:  2012-12-13       Impact factor: 2.689

9.  Prognostic impact of left ventricular mass change in patients with ST-elevation myocardial infarction.

Authors:  Jin-Sun Park; Jeoung-Sook Shin; You-Hong Lee; Kyoung-Woo Seo; Byoung-Joo Choi; So-Yeon Choi; Myeong-Ho Yoon; Gyo-Seung Hwang; Seung-Jea Tahk; Joon-Han Shin
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

10.  Severity Indices for Obstructive Sleep Apnea Syndrome Reflecting Glycemic Control or Insulin Resistance.

Authors:  Yuki Isobe; Yasuto Nakatsumi; Yu Sugiyama; Takuto Hamaoka; Hisayoshi Murai; Masayuki Takamura; Shuichi Kaneko; Shigeo Takata; Toshinari Takamura
Journal:  Intern Med       Date:  2019-07-22       Impact factor: 1.271

View more
  3 in total

Review 1.  Sleep Apnea and Hypertension.

Authors:  Gino Seravalle; Guido Grassi
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-11-05

2.  Influencing Factors of Daytime Sleepiness in Patients with Obstructive Sleep Apnea Hypopnea Syndrome and Its Correlation with Pulse Oxygen Decline Rate.

Authors:  Fengying Zhang; Xijiang Wu; Wenping Duan; Fangfang Wang; Tingting Huang; Meiling Xiang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-13       Impact factor: 2.629

3.  Characteristics of hypertension and arterial stiffness in obstructive sleep apnea: A Scandinavian experience from a prospective study of 6408 normotensive and hypertensive patients.

Authors:  Sahrai Saeed; Andrea Romarheim; Giuseppe Mancia; Ingvild West Saxvig; Shashi Gulati; Sverre Lehmann; Bjørn Bjorvatn
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-02-14       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.